Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early migraine drug use may stop headaches in their tracks

NCT ID NCT07310290

Recruiting now Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 23 times

Summary

This study looks at whether taking the migraine drug ubrogepant during the earliest signs of a migraine (called the prodrome phase) can prevent moderate to severe headache pain. About 189 adults who already use ubrogepant will take it as prescribed and report their symptoms over 13 weeks. The goal is to see if early treatment reduces headache severity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chicago Headache Center & Research Inst /ID# 272345

    RECRUITING

    Naperville, Illinois, 60563, United States

  • Neurology and Pain Specialty Center /ID# 278508

    RECRUITING

    Aliso Viejo, California, 92656, United States

  • Tri City Research Center, LLC /ID# 278800

    RECRUITING

    Grand Island, Nebraska, 68803, United States

Conditions

Explore the condition pages connected to this study.

MIGRAINE